| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.79M | 14.13M | 6.99M | 13.61M | 18.04M | 3.13M | 20.72M | 37K |
| Revenue Growth % | - | 1.44% | -0.51% | 0.95% | 0.33% | -0.83% | 5.62% | -1% |
| Cost of Goods Sold | 13.57M | 18.36M | 38.72M | 53.04M | 61.36M | 80.25M | 97.1M | 0 |
| COGS % of Revenue | 2.34% | 1.3% | 5.54% | 3.9% | 3.4% | 25.65% | 4.69% | - |
| Gross Profit | -7.78M | -4.23M | -31.73M | -39.43M | -43.32M | -77.12M | -76.37M | 37K |
| Gross Margin % | -1.34% | -0.3% | -4.54% | -2.9% | -2.4% | -24.65% | -3.69% | 1% |
| Gross Profit Growth % | - | 0.46% | -6.5% | -0.24% | -0.1% | -0.78% | 0.01% | 1% |
| Operating Expenses | 17.06M | 24.53M | 19.03M | 17.24M | 28.01M | 32.91M | 36.49M | 187.88M |
| OpEx % of Revenue | 2.95% | 1.74% | 2.72% | 1.27% | 1.55% | 10.52% | 1.76% | 5077.78% |
| Selling, General & Admin | 3.49M | 6.17M | 13.89M | 17.24M | 28.01M | 32.91M | 36.49M | 46.58M |
| SG&A % of Revenue | 0.6% | 0.44% | 1.99% | 1.27% | 1.55% | 10.52% | 1.76% | 1258.89% |
| Research & Development | 13.57M | 18.36M | 43.85M | 53.04M | 61.36M | 80.25M | 97.1M | 141.3M |
| R&D % of Revenue | 2.34% | 1.3% | 6.28% | 3.9% | 3.4% | 25.65% | 4.69% | 3818.89% |
| Other Operating Expenses | -40K | -2K | -38.72M | -53.04M | -61.36M | -80.25M | -97.1M | 0 |
| Operating Income | -11.27M | -10.4M | -50.76M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M |
| Operating Margin % | -1.95% | -0.74% | -7.27% | -4.16% | -3.95% | -35.17% | -5.45% | -5076.78% |
| Operating Income Growth % | - | 0.08% | -3.88% | -0.12% | -0.26% | -0.54% | -0.03% | -0.66% |
| EBITDA | -10.65M | -9.7M | -49.76M | -55.22M | -69.81M | -107.63M | -108.66M | -181.14M |
| EBITDA Margin % | -1.84% | -0.69% | -7.12% | -4.06% | -3.87% | -34.4% | -5.24% | -4895.57% |
| EBITDA Growth % | - | 0.09% | -4.13% | -0.11% | -0.26% | -0.54% | -0.01% | -0.67% |
| D&A (Non-Cash Add-back) | 626K | 697K | 1M | 1.44M | 1.52M | 2.4M | 4.2M | 6.71M |
| EBIT | -11.27M | -10.4M | -45.63M | -56.66M | -71.33M | -110.03M | -112.87M | -187.84M |
| Net Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M |
| Interest Income | 89K | 850K | 1.5M | 152K | 137K | 2.57M | 12.21M | 27.05M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 49K | 848K | 1.46M | -29K | 16K | 2.54M | 12.03M | 26.97M |
| Pretax Income | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M |
| Pretax Margin % | -1.94% | -0.68% | -7.06% | -4.16% | -3.95% | -34.35% | -4.87% | -4347.78% |
| Income Tax | -89K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M |
| Net Margin % | -1.94% | -0.68% | -7.06% | -4.16% | -3.95% | -34.35% | -4.87% | -4347.78% |
| Net Income Growth % | - | 0.15% | -4.16% | -0.15% | -0.26% | -0.51% | 0.06% | -0.6% |
| Net Income (Continuing) | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.76 | -0.76 | -2.00 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 |
| EPS Growth % | - | 0% | -1.63% | -0.06% | -0.16% | -0.27% | 0.17% | -0.16% |
| EPS (Basic) | -0.76 | -0.76 | -2.00 | -2.12 | -2.46 | -3.12 | -2.58 | -2.98 |
| Diluted Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M |
| Basic Shares Outstanding | 14.84M | 12.52M | 26.49M | 26.68M | 27.73M | 32.35M | 39.13M | 53.94M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 24.5M | 94.07M | 52.51M | 282.66M | 256.28M | 220.51M | 296.59M | 434.93M |
| Cash & Short-Term Investments | 23.85M | 91.76M | 49.65M | 276.73M | 247.78M | 213.55M | 288.23M | 424.88M |
| Cash Only | 23.85M | 91.76M | 49.65M | 276.73M | 153M | 52.35M | 249.11M | 149.34M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 94.78M | 161.2M | 39.12M | 275.54M |
| Accounts Receivable | 321K | 1.12M | 978K | 1.49M | 47K | 700K | 0 | 0 |
| Days Sales Outstanding | 20.24 | 29.03 | 51.1 | 39.85 | 0.95 | 81.66 | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 4.44M | 0 | 6.26M | 8.36M | 10.05M |
| Total Non-Current Assets | 2.82M | 2.9M | 5.73M | 5.67M | 97.21M | 41.34M | 43.3M | 125.45M |
| Property, Plant & Equipment | 2.72M | 2.47M | 5.05M | 5.07M | 28.95M | 35.35M | 31.66M | 40.61M |
| Fixed Asset Turnover | 2.13x | 5.72x | 1.38x | 2.68x | 0.62x | 0.09x | 0.65x | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 67.65M | 4.91M | 10.95M | 80.58M |
| Other Non-Current Assets | 105K | 429K | 677K | 602K | 602K | 1.08M | 684K | 4.26M |
| Total Assets | 27.32M | 96.97M | 58.23M | 288.33M | 353.49M | 261.85M | 339.89M | 560.38M |
| Asset Turnover | 0.21x | 0.15x | 0.12x | 0.05x | 0.05x | 0.01x | 0.06x | 0.00x |
| Asset Growth % | - | 2.55% | -0.4% | 3.95% | 0.23% | -0.26% | 0.3% | 0.65% |
| Total Current Liabilities | 5.91M | 8.05M | 12.96M | 16.74M | 16.34M | 15.73M | 18.95M | 29.15M |
| Accounts Payable | 460K | 954K | 1.74M | 1.79M | 4.76M | 3.32M | 3.52M | 4.39M |
| Days Payables Outstanding | 12.37 | 18.96 | 16.44 | 12.3 | 28.34 | 15.11 | 13.21 | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 2.65M | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 1000K | 884K | 273K | 257K |
| Other Current Liabilities | 279K | 0 | 0 | 0 | 0 | 3.18M | 3.87M | 0 |
| Current Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x |
| Quick Ratio | 4.15x | 11.68x | 4.05x | 16.88x | 15.69x | 14.02x | 15.65x | 14.92x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 41M | 116.5M | 118.25M | 15.2M | 18.04M | 14.78M | 13.11M | 20.63M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 15.22M | 13.47M | 11.52M | 18.97M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 18.81M | 103.43M | 104.65M | 1.97M | 334K | 233K | 617K | 603K |
| Total Liabilities | 46.91M | 124.56M | 131.2M | 31.94M | 34.38M | 30.51M | 32.06M | 49.78M |
| Total Debt | 0 | 0 | 0 | 0 | 16.45M | 16.12M | 14.67M | 24.61M |
| Net Debt | -23.85M | -91.76M | -49.65M | -276.73M | -136.55M | -36.23M | -234.44M | -124.73M |
| Debt / Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -19.59M | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M |
| Equity Growth % | - | -0.41% | -1.65% | 4.51% | 0.24% | -0.28% | 0.33% | 0.66% |
| Book Value per Share | -1.32 | -2.20 | -2.75 | 9.61 | 11.51 | 7.15 | 7.87 | 9.47 |
| Total Shareholders' Equity | -19.59M | -27.59M | -72.97M | 256.39M | 319.11M | 231.34M | 307.83M | 510.61M |
| Common Stock | 1K | 1K | 1K | 3K | 3K | 3K | 4K | 5K |
| Retained Earnings | -20.48M | -30.03M | -79.03M | -135.68M | -207M | -314.49M | -415.33M | -576.2M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -18.51M | -102.98M | -102.98M | -288.33M | -423K | -1.2M | 16K | 229K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 8.24M | -16.25M | -36.71M | -50.91M | -69.13M | -86.69M | -75.79M | -134.59M |
| Operating CF Margin % | 1.42% | -1.15% | -5.25% | -3.74% | -3.83% | -27.7% | -3.66% | -3637.43% |
| Operating CF Growth % | - | -2.97% | -1.26% | -0.39% | -0.36% | -0.25% | 0.13% | -0.78% |
| Net Income | -11.22M | -9.55M | -49.31M | -56.69M | -71.32M | -107.49M | -100.84M | -160.87M |
| Depreciation & Amortization | 626K | 697K | 1M | 1.44M | 3.02M | 3.88M | 5.75M | 6.71M |
| Stock-Based Compensation | 256K | 1.38M | 0 | 4.98M | 13.8M | 0 | 19.66M | 26.12M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 39K | 2K | 11.33M | 69K | 898K | 18.27M | -999K | -7.08M |
| Working Capital Changes | 18.54M | -8.78M | 259K | -712K | -15.53M | -1.34M | 630K | 537K |
| Change in Receivables | -320K | -803K | 146K | -508K | 1.44M | 47K | 0 | 0 |
| Change in Inventory | -53K | 175K | 0 | 0 | -4.54M | 0 | 0 | 0 |
| Change in Payables | -114K | 438K | 533K | 43K | 2.29M | -1.64M | 896K | 871K |
| Cash from Investing | 7.67M | -414K | -3.2M | -1M | -172.68M | -17.05M | 115.72M | -302.44M |
| Capital Expenditures | -573K | -414K | -3.2M | -1M | -9.11M | -11.54M | -2.77M | -3.79M |
| CapEx % of Revenue | 0.1% | 0.03% | 0.46% | 0.07% | 0.51% | 3.69% | 0.13% | 102.32% |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 24K | 0 | 0 | 0 | -9.11M | 0 | 173.29M | 0 |
| Cash from Financing | 16K | 84.58M | -2.19M | 278.98M | 118.09M | 3.08M | 156.83M | 337.25M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 0 | 84.58M | 0 | 857K | 3.79M | 0 | 8.49M | 5.84M |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | 7.66M | -16.67M | -39.91M | -51.91M | -78.24M | -98.22M | -78.56M | -138.37M |
| FCF Margin % | 1.32% | -1.18% | -5.71% | -3.81% | -4.34% | -31.39% | -3.79% | -3739.76% |
| FCF Growth % | - | -3.17% | -1.39% | -0.3% | -0.51% | -0.26% | 0.2% | -0.76% |
| FCF per Share | 0.52 | -1.33 | -1.51 | -1.95 | -2.82 | -3.04 | -2.01 | -2.57 |
| FCF Conversion (FCF/Net Income) | -0.73x | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | -61.82% | -24.78% | -39.06% | -37.4% | -39.31% |
| Return on Invested Capital (ROIC) | - | - | - | - | -65.96% | -43.7% | -63.05% | -61.35% |
| Gross Margin | -134.42% | -29.95% | -454.22% | -289.64% | -240.17% | -2464.81% | -368.54% | 100% |
| Net Margin | -193.83% | -67.59% | -705.78% | -416.49% | -395.37% | -3435.41% | -486.59% | -434778.38% |
| Debt / Equity | - | - | - | - | 0.05x | 0.07x | 0.05x | 0.05x |
| FCF Conversion | -0.73x | 1.70x | 0.74x | 0.90x | 0.97x | 0.81x | 0.75x | 0.84x |
| Revenue Growth | - | 144.04% | -50.56% | 94.85% | 32.52% | -82.65% | 562.29% | -99.82% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Collaboration And License Revenue | 13.61M | 18.04M | 3.13M | 20.01M | 37K |
| Collaboration And License Revenue Growth | - | 32.52% | -82.65% | 539.44% | -99.82% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| UNITED STATES | -27K | 121K | 35K | 20.16M | 37K |
| UNITED STATES Growth | - | 548.15% | -71.07% | 57488.57% | -99.82% |
| NETHERLANDS | 742K | 736K | 3.09M | 567K | - |
| NETHERLANDS Growth | - | -0.81% | 320.38% | -81.67% | - |
| SWITZERLAND | 12.9M | 17.18M | - | - | - |
| SWITZERLAND Growth | - | 33.22% | - | - | - |
| AUSTRALIA | - | - | - | - | - |
| AUSTRALIA Growth | - | - | - | - | - |
4D Molecular Therapeutics, Inc. (FDMT) reported $0.1M in revenue for fiscal year 2024. This represents a 98% decrease from $5.8M in 2017.
4D Molecular Therapeutics, Inc. (FDMT) saw revenue decline by 99.8% over the past year.
4D Molecular Therapeutics, Inc. (FDMT) reported a net loss of $209.2M for fiscal year 2024.
4D Molecular Therapeutics, Inc. (FDMT) has a return on equity (ROE) of -39.3%. Negative ROE indicates the company is unprofitable.
4D Molecular Therapeutics, Inc. (FDMT) had negative free cash flow of $185.1M in fiscal year 2024, likely due to heavy capital investments.